Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · IEX Real-Time Price · USD
9.16
-0.04 (-0.43%)
Apr 19, 2024, 2:20 PM EDT - Market open
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for TBPH stock have an average target of 20.5, with a low estimate of 20 and a high estimate of 21. The average target predicts an increase of 123.80% from the current stock price of 9.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TBPH stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Initiates $21 | Strong Buy | Initiates | $21 | +129.26% | Apr 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +118.34% | Aug 8, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $19 → $20 | Strong Buy | Maintains | $19 → $20 | +118.34% | May 9, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +107.42% | Feb 28, 2023 |
| SVB Leerink | SVB Leerink | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +52.84% | Nov 17, 2022 |
Financial Forecast
Revenue This Year
75.82M
from 57.42M
Increased by 32.03%
Revenue Next Year
88.10M
from 75.82M
Increased by 16.20%
EPS This Year
-0.66
from -1.00
EPS Next Year
-0.33
from -0.66
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 91.9M | 101.4M | 179.6M | 236.6M | 400.6M |
| Avg | 75.8M | 88.1M | 125.9M | 147.2M | 209.5M |
| Low | 62.6M | 75.4M | 75.7M | 78.4M | 83.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 60.0% | 33.7% | 103.8% | 88.0% | 172.1% |
| Avg | 32.0% | 16.2% | 42.9% | 17.0% | 42.3% |
| Low | 9.0% | -0.5% | -14.1% | -37.7% | -43.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.32 | 0.34 | 2.25 | 1.49 | 3.77 |
| Avg | -0.66 | -0.33 | 1.30 | 1.41 | 2.75 |
| Low | -0.94 | -0.73 | 0.66 | 1.31 | 1.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 15.1% | 167.8% |
| Avg | - | - | - | 8.7% | 95.7% |
| Low | - | - | - | 1.4% | 26.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.